Search for: "Boehringer Ingelheim, Inc."
Results 121 - 140
of 155
Sorted by Relevance
|
Sort by Date
28 Jul 2013, 9:29 am
Some of the other diabetes drugs being investigated include Bydureon and Onglyza, sold by Bristol-Myers Squibb; AstraZeneca and Victoza from Novo Nordisk; Tradjenta from Eli Lilly and Boehringer Ingelheim; and Nesina from Takeda. [read post]
17 Oct 2007, 8:59 am
And now the tipping point is in sight as more law departments and law firms inch towards greater use of evaluations and assessments-- and trumpet the benefits.General Counsel Scott Terrillion, of Boehringer Ingelheim Pharmaceuticals Inc, uses an "evaluative selection method" to find the best attorneys for his company, with diversity being a natural consequence. [read post]
5 Jun 2014, 7:06 am
Boehringer Ingelheim Pharmaceuticals, Inc., which was decided just a few months before I started my career in employment law. [read post]
31 Jan 2011, 8:10 am
Terminal Disclaimers and Section 121 Boehringer Ingelheim International GmbH v. [read post]
31 Jan 2011, 8:10 am
Terminal Disclaimers and Section 121 Boehringer Ingelheim International GmbH v. [read post]
8 Jul 2015, 8:31 am
., Inc., 625 F.2d 1055 (3d Cir. 1980) (holding unique coloring of prescription drug capsule constituted protectable trade dress); Boehringer Ingelheim G.m.b.H. v. [read post]
8 Jan 2016, 8:00 pm
Boehringer Ingelheim Pharmaceuticals v. [read post]
27 Jan 2010, 3:00 am
- ‘indirect consumer tax’ to fund UN public health initiatives (Afro-IP) Canada: Submissions on Canada-EU trade deal: Canadian Generic Pharma Assoc. wants IP out (Michael Geist) Canada: Intellectual property and agriculture – CDC Triffid seed story (ipblog.ca) EU: Records of the 1st, 2nd and 3rd expert meetings on SPCs (The SPC Blog) EU: Cooperation between Board of Appeal and National Court / acceleration of appeal proceedings: Human Genome Sciences v Eli Lilly (EPLAW) Indian… [read post]
15 Nov 2016, 2:00 pm
Boehringer Ingelheim GMBH, 237F.3d 1359, 1365 (Fed. [read post]
3 Mar 2010, 5:05 am
(IP Think Tank) US: Reverse payments in generic drug settlements (Part II - Patent Docs) (Part III - Patent Docs) (Part IV - Patent Docs) US: Inability of patent examiner and Board to correctly read prior art reference necessitates intervention by Federal Circuit: In re Chapman (Holman's Biotech IP Blog) (Patent Docs) US: Patent infringement suit between NexMed and Beta Technologies stayed following determination that plaintiff NexMed may not own one of the patents-in-suit related to method of… [read post]
9 Nov 2012, 2:15 pm
" November 7, 2012: "Interim Results from RELY-ABLE®, the RE-LY® Extension Study, Provide Additional Clinical Evidence for the Safety of Pradaxa® (dabigatran etexilate mesylate)" (Drug company Press Release) @EXCERPT: Boehringer Ingelheim Pharmaceuticals, Inc. today announced interim results from the RELY-ABLE® trial, a long-term extension of the RE-LY® study. [read post]
3 Mar 2010, 5:05 am
(IP Think Tank) US: Reverse payments in generic drug settlements (Part II - Patent Docs) (Part III - Patent Docs) (Part IV - Patent Docs) US: Inability of patent examiner and Board to correctly read prior art reference necessitates intervention by Federal Circuit: In re Chapman (Holman's Biotech IP Blog) (Patent Docs) US: Patent infringement suit between NexMed and Beta Technologies stayed following determination that plaintiff NexMed may not own one of the patents-in-suit related to method of… [read post]
12 Jul 2011, 6:59 am
The trouble started when Lilly entered a different agreement this year with Amylin competitor Boehringer Ingelheim to sell a rival diabetes drug: BI’s Tradjenta. [read post]
9 Aug 2011, 4:30 am
Boehringer Ingelheim Pharma., Inc., C.A. [read post]
14 Jun 2010, 1:07 pm
That decision was challenged in court, see Boehringer Ingelheim Corp. v. [read post]
4 Sep 2018, 7:00 am
Boehringer Ingelheim Pharmaceuticals, Inc., 892 F.3d 1264 (D.C. [read post]
4 Sep 2018, 7:00 am
Boehringer Ingelheim Pharmaceuticals, Inc., 892 F.3d 1264 (D.C. [read post]
31 Jan 2013, 12:57 pm
The plaintiffs brought a product liability claim against Boehringer Ingelheim Pharmaceuticals, Inc. [read post]
8 Sep 2020, 6:56 am
Boehringer Ingelheim Pharms., Inc., 2020 WL 5258317, No. 19-5321 (E.D. [read post]
17 Jun 2010, 6:47 am
Abbott Laboratories, Inc. [read post]
